IL‐23/IL‐17 axis in IBD

@article{Sarra2010IL23IL17AI,
  title={IL‐23/IL‐17 axis in IBD},
  author={Massimiliano Sarra and Francesco Pallone and Thomas T. Macdonald and Giovanni Monteleone},
  journal={Inflammatory Bowel Diseases},
  year={2010},
  volume={16},
  pages={1808–1813}
}
&NA; Gut inflammation occurring in patients with Crohn's disease and patients with ulcerative colitis has been traditionally associated with an exaggerated Th1 or Th2 cell response, respectively. However, recent studies have shown that in both inflammatory bowel diseases (IBD) there is also enhanced synthesis of cytokines made by a distinct subset of T helper cells, termed Th17 cells. The discovery that this new T‐cell subset drives immune‐mediated pathology in the gut, and that interleukin (IL… 
TH1 and TH17 interactions in untreated inflamed mucosa of inflammatory bowel disease, and their potential to mediate the inflammation.
TLDR
TH1 and TH17 cytokines seem to act synergistically in inflammatory bowel disease (IBD) with no apparent polarization between UC and CD.
Th17 Cells as Potential Probiotic Therapeutic Targets in Inflammatory Bowel Diseases
TLDR
This review highlights critical roles of Th 17 cells in the pathogenesis of IBD and the rationale for using probiotics as a novel therapeutic approach for IBD through manipulation of Th17 cells.
Alterations in cytokine gene expression profile in colon mucosa of Inflammatory Bowel Disease patients on different therapeutic regimens
TLDR
Treatment with immunosuppressive therapy was more beneficial for driving cytokine expression to restore immune regulation in patients with IBD, unlike the 5‐ASA therapy.
Master regulator of intestinal disease: IL-6 in chronic inflammation and cancer development.
TLDR
Although clinical data about anti-IL-6 treatment in intestinal diseases are currently scarce, targeting this pathway might be a promising strategy in IBD and CRC.
Biological therapy targeting the IL-23/IL-17 axis in inflammatory bowel disease
TLDR
A new era in IBD treatment has recently been initiated: besides immunomodulators and TNF-antagonists, anti-adhesion molecules and monoclonal antibodies targeting the IL-23/IL-17 pathway have been developed, which will further improve disease-related and patient-reported outcome.
Cytokines in Inflamed Mucosa of IBD Patients
TLDR
In order to achieve immune homeostasis in the gut, pro-inflammatory and anti-inflammatory responses that define the mucosal cell immunophenotype should achieve balance.
Innate and adaptive immunity in inflammatory bowel disease.
Inflammatory bowel disease (IBD) includes Crohn's disease (CD) and ulcerative colitis (UC). The exact cause of IBD remains unknown. Available evidence suggests that an abnormal immune response
Crohn’s Disease and Ulcerative Colitis Show Unique Cytokine Profiles
TLDR
The unique patterns of cytokine networks can help to better understand the differential expression of their characteristic pathophysiology and the pharmacological regulation of these small molecules may hold promise to more effective and personalized therapies.
Targets for new immunomodulation strategies in inflammatory bowel disease.
TLDR
Some of the major immunological defects documented in IBD are reviewed and why compounds inhibiting soluble cytokines were not beneficial in patients and how to optimize therapeutic strategies with biologics are discussed.
Th17 cells: interactions with predisposing factors in the immunopathogenesis of inflammatory bowel disease
TLDR
Understanding the role of Th17 cells in IBD pathogenesis and targeting their regulatory cytokines may provide potential therapeutic approaches for the treatment of IBD in the future.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 72 REFERENCES
Critical role of IL‐17 receptor signaling in acute TNBS‐induced colitis
TLDR
It is demonstrated that IL‐17R signaling plays a critical role in the development of TNBS‐induced colitis and may represent a target for therapeutic intervention for IBD.
IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6.
TLDR
This study shows that in these models, IL-23 is essential for manifestation of chronic intestinal inflammation, whereas IL-12 is not, and a critical target of IL- 23 is a unique subset of tissue-homing memory T cells, which are specifically activated by IL-21 to produce the proinflammatory mediators IL-17 and IL-6.
IL-23 plays a key role in Helicobacter hepaticus–induced T cell–dependent colitis
TLDR
The data demonstrate that IL-23 and not IL-12 is essential for the development of maximal intestinal disease, and support a model in which IL- 23 drives both interferon γ and IL-17 responses that together synergize to trigger severe intestinal inflammation.
Regulation of gut inflammation and th17 cell response by interleukin-21.
TLDR
Results indicate that IL-21 is a critical regulator of inflammation and Th17 cell responses in the gut, as shown in mice induced with dextran sulfate sodium- and trinitrobenzene sulfonic acid-relapsing colitis.
Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease.
TLDR
It is shown that IL-22 protected mice from IBD, and Interestingly, not only was this protection mediated by CD4+ T cells, but IL- 22-expressing natural killer (NK) cells also conferred protection.
IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis.
TLDR
A novel microinjection-based local gene-delivery system that is capable of targeting the inflamed intestine and demonstrating a therapeutic potency for IL-22-mediated activation of the innate immune pathway in a mouse model of Th2-mediated colitis that induces disease with characteristics similar to that of IBD ulcerative colitis is developed.
A protective function for interleukin 17A in T cell–mediated intestinal inflammation
TLDR
IL-17A-mediated protection in the CD45RBhi transfer model of colitis is demonstrated and T cells are identified as not only the source but also a target of IL-17 in vivo.
Interleukin-23 drives innate and T cell–mediated intestinal inflammation
TLDR
IL-23 is newly identified as a driver of innate immune pathology in the intestine and selective targeting of IL-23 represents an attractive therapeutic approach in human IBD.
Differential regulation of interleukin 17 and interferon γ production in inflammatory bowel disease
TLDR
A role for IL12, TGFβ and IL21 in modulating IL17/IFNγ production in IBD is supported, and the abundant IL17 in inflamed IBD mucosa may help explain the relative lack of efficacy of anti-IFnγ antibodies in clinical trials of Crohn’s disease.
Interleukin-23 Restrains Regulatory T Cell Activity to Drive T Cell-Dependent Colitis
TLDR
It is shown that overriding immunosuppressive pathways is an important function of IL-23 in the intestine and could influence not only Th17 cell activity but also other types of immune responses.
...
1
2
3
4
5
...